Evidence map›Paper›PMID 41312388›Full record

ArticleiScience2025

ATP6V0D2 drives triple-negative breast cancer progression and inhibits cisplatin sensitivity by promoting PHLPP2 lysosomal degradation.

Jingyu Zhang, Congbo Cao, Hongyu Yang, Liu Yang, Meiqi Wang, Xiaohan Liu, Xin Hao, Yuanyuan Zhang, Xiaohan Wang, Zhenchuan Song

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jingyu ZhangDepartment of Breast Disease Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China.
Congbo CaoDepartment of Breast Disease Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China.
Hongyu YangState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Liu YangDepartment of Breast Disease Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China.
Meiqi WangDepartment of Breast Disease Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China.
Xiaohan LiuDepartment of Breast Disease Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China.
Xin HaoDepartment of Breast Disease Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China.
Yuanyuan ZhangState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Xiaohan WangDepartment of Breast Disease Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China.
Zhenchuan SongDepartment of Breast Disease Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) faces therapeutic challenges due to limited treatment options and frequent chemoresistance. In this study, we identify ATP6V0D2 as a key factor upregulated in TNBC, where its expression correlates with poor prognosis. Transcriptomic and functional analyses linked ATP6V0D2 to PI3K/AKT signaling and platinum drug resistance. Mechanistically, ATP6V0D2 enhanced lysosomal function to promote degradation of the tumor suppressor PHLPP2, thereby sustaining AKT phosphorylation. Functional assays showed that ATP6V0D2 knockdown increased cisplatin sensitivity both

Indexed as

CancerTarget identificationTherapeutics

Identifiers

PMID41312388
PMCPMC12648496

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.